NVO
Novo Nordisk A/S · Healthcare
36.62
0.15%(-0.06)
Market OpenLast Updated: — ET
52W L: $35.1252W H: $81.44
$36.60
CHG-2.14 (-5.52%)
H$40.09
L$35.06
VOL304M
NVO (1h)
Novo Nordisk A/S · Healthcare
Novo Nordisk's weight loss pill is expanding the obesity treatment market as an alternative to injectable GLP-1 medications. CNBC spoke with patients about their experience on the pill and explains how the drug is facing competition from Eli Lilly's oral weight loss pill.
Novo Nordisk announced on Tuesday that it is making a higher-dose version of its popular weight-loss medication, Wegovy, available across the United States. The new 7.2-milligram dose, branded as Wegovy HD, was recently approved under the FDA Commissioner's National Priority Review Voucher program last month, marking a significant development in obesity treatment options.
Top insights from the latest market news from Tuesday, April 7, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
Wegovy HD—offering the highest weight-loss of any Wegovy injection so far—is now available nationwide, the compay said.
Novo Nordisk said on Tuesday that it has made a higher-dose version of its blockbuster weight-loss drug Wegovy available across the United States.
Here are five key things investors need to know to start the trading day.
No recent filings